Mitomycin C Use in Keloid Treatment
The evidence does not support routine use of Mitomycin C for keloid treatment, as the available data shows inconsistent results and no clear benefit over standard therapies. While Mitomycin C has theoretical appeal as an anti-fibrotic agent, the clinical evidence specific to keloids is limited and contradictory.
Evidence Assessment
The provided evidence base is problematic for answering this question about keloids:
Most guidelines address corneal scarring, not keloids 1, 2, 1, 2. These ophthalmology guidelines describe Mitomycin C use at 0.02% (0.2 mg/mL) for 12-120 seconds to prevent corneal scarring after keratectomy, but this is an entirely different tissue type and pathophysiology than keloid formation.
One guideline mentions scarification complications 3, 4 but provides no specific protocol for Mitomycin C in keloid management.
The FDA label 5 describes only intravenous administration for cancer chemotherapy and explicitly notes that Mitomycin C is not FDA-approved for dermatologic or ophthalmic use. The label warns of serious toxicities including bone marrow suppression, tissue necrosis with extravasation, and renal toxicity.
Research Evidence on Keloids
The research studies show conflicting results:
Negative findings:
- A 2005 study found no difference in keloid recurrence when topical Mitomycin C (0.4 mg/mL for 5 minutes) was applied after surgical excision 6. Four of 12 patients had recurrence at both treated and control sites, while 10 had no recurrence at either site.
Mixed findings:
A 2012 study reported good results with topical Mitomycin C (1 mg/mL for 3 minutes) after shave excision, with 6 of 9 patients very satisfied 7. However, intralesional injection worsened both cases, causing increased ulceration.
A 2021 study comparing topical versus intralesional Mitomycin C found both reduced Vancouver Scar Scale scores, but topical application showed better outcomes and satisfaction than intralesional injection 8.
Positive findings:
A 2025 study found intralesional Mitomycin C (0.4 mg/dL) more effective than triamcinolone for reducing scar size and VSS scores 9.
A 2011 case series of 26 pinnae keloids treated with shave excision plus topical Mitomycin C reported no recurrences over 6-24 months 10.
Current Standard of Care
Recent comprehensive reviews 11, 12, 13 establish that:
- Intralesional corticosteroids remain first-line treatment for keloids
- Combination therapies outperform monotherapy, particularly corticosteroids plus 5-fluorouracil
- Surgical excision combined with adjuvant radiotherapy reduces recurrence to below 10%
- Mitomycin C is not mentioned as a standard or recommended therapy in current keloid management algorithms
Clinical Recommendation
If considering Mitomycin C for keloids (off-label use):
Reserve for refractory cases only after failure of standard therapies (intralesional corticosteroids, 5-fluorouracil, cryotherapy)
Use topical application only - never intralesional injection, which has caused worsening 7
Protocol (if used):
- Concentration: 0.4-1.0 mg/mL
- Application time: 3-5 minutes
- Apply to wound bed immediately after surgical shave excision
- Use saturated cellulose sponge, ensuring no spread beyond treatment area
- Copious irrigation with saline immediately after to prevent tissue toxicity
Informed consent is mandatory - explain this is off-label use, not FDA-approved, with uncertain efficacy and potential for tissue necrosis
Monitor for complications: delayed wound healing, tissue necrosis, hypopigmentation
Critical Caveats
- No standardized protocol exists - dosing, concentration, and application time vary widely across studies
- Risk of tissue damage - the same cytotoxic properties that inhibit fibroblasts can cause necrosis and delayed healing
- Better alternatives exist - combination corticosteroid/5-FU therapy or surgery plus radiation have stronger evidence 11, 12
- Patient selection matters - those with personal or family history of keloids should be counseled about uncertain outcomes 4
The most prudent approach is to use established first-line therapies (intralesional triamcinolone, combination with 5-fluorouracil) rather than Mitomycin C, which lacks robust evidence and carries significant risks when used for keloid treatment.